Bio Plus Co., Ltd

KOSDAQ:A099430 Stock Report

Market Cap: ₩331.3b

Bio Plus Balance Sheet Health

Financial Health criteria checks 4/6

Bio Plus has a total shareholder equity of ₩189.1B and total debt of ₩58.4B, which brings its debt-to-equity ratio to 30.9%. Its total assets and total liabilities are ₩293.5B and ₩104.4B respectively. Bio Plus's EBIT is ₩27.9B making its interest coverage ratio -48.5. It has cash and short-term investments of ₩31.9B.

Key information

30.90%

Debt to equity ratio

₩58.42b

Debt

Interest coverage ratio-48.5x
Cash₩31.87b
Equity₩189.07b
Total liabilities₩104.40b
Total assets₩293.47b

Recent financial health updates

Bio Plus (KOSDAQ:099430) Seems To Use Debt Quite Sensibly

Aug 18
Bio Plus (KOSDAQ:099430) Seems To Use Debt Quite Sensibly

Does Bio Plus (KOSDAQ:099430) Have A Healthy Balance Sheet?

Feb 14
Does Bio Plus (KOSDAQ:099430) Have A Healthy Balance Sheet?

Recent updates

We Think That There Are More Issues For Bio Plus (KOSDAQ:099430) Than Just Sluggish Earnings

Nov 27
We Think That There Are More Issues For Bio Plus (KOSDAQ:099430) Than Just Sluggish Earnings

Bio Plus' (KOSDAQ:099430) Dividend Will Be ₩50.00

Nov 10
Bio Plus' (KOSDAQ:099430) Dividend Will Be ₩50.00

Bio Plus (KOSDAQ:099430) Seems To Use Debt Quite Sensibly

Aug 18
Bio Plus (KOSDAQ:099430) Seems To Use Debt Quite Sensibly

Capital Allocation Trends At Bio Plus (KOSDAQ:099430) Aren't Ideal

Jul 22
Capital Allocation Trends At Bio Plus (KOSDAQ:099430) Aren't Ideal

What Bio Plus Co., Ltd's (KOSDAQ:099430) 26% Share Price Gain Is Not Telling You

May 09
What Bio Plus Co., Ltd's (KOSDAQ:099430) 26% Share Price Gain Is Not Telling You

Bio Plus' (KOSDAQ:099430) Anemic Earnings Might Be Worse Than You Think

Mar 31
Bio Plus' (KOSDAQ:099430) Anemic Earnings Might Be Worse Than You Think

Does Bio Plus (KOSDAQ:099430) Have A Healthy Balance Sheet?

Feb 14
Does Bio Plus (KOSDAQ:099430) Have A Healthy Balance Sheet?

Bio Plus Co., Ltd's (KOSDAQ:099430) Shares Climb 30% But Its Business Is Yet to Catch Up

Jan 07
Bio Plus Co., Ltd's (KOSDAQ:099430) Shares Climb 30% But Its Business Is Yet to Catch Up

Bio Plus (KOSDAQ:099430) Is Reinvesting At Lower Rates Of Return

Dec 15
Bio Plus (KOSDAQ:099430) Is Reinvesting At Lower Rates Of Return

Bio Plus Co., Ltd's (KOSDAQ:099430) Shareholders Might Be Looking For Exit

Nov 23
Bio Plus Co., Ltd's (KOSDAQ:099430) Shareholders Might Be Looking For Exit

Earnings Not Telling The Story For Bio Plus Co., Ltd (KOSDAQ:099430) After Shares Rise 29%

Jul 23
Earnings Not Telling The Story For Bio Plus Co., Ltd (KOSDAQ:099430) After Shares Rise 29%

The Returns On Capital At Bio Plus (KOSDAQ:099430) Don't Inspire Confidence

Jul 05
The Returns On Capital At Bio Plus (KOSDAQ:099430) Don't Inspire Confidence

More Unpleasant Surprises Could Be In Store For Bio Plus Co., Ltd's (KOSDAQ:099430) Shares After Tumbling 31%

Jun 08
More Unpleasant Surprises Could Be In Store For Bio Plus Co., Ltd's (KOSDAQ:099430) Shares After Tumbling 31%

Additional Considerations Required While Assessing Bio Plus' (KOSDAQ:099430) Strong Earnings

Mar 26
Additional Considerations Required While Assessing Bio Plus' (KOSDAQ:099430) Strong Earnings

Financial Position Analysis

Short Term Liabilities: A099430's short term assets (₩85.8B) do not cover its short term liabilities (₩94.3B).

Long Term Liabilities: A099430's short term assets (₩85.8B) exceed its long term liabilities (₩10.1B).

Debt to Equity History and Analysis

Debt Level: A099430's net debt to equity ratio (14%) is considered satisfactory.

Reducing Debt: A099430's debt to equity ratio has increased from 0% to 30.9% over the past 5 years.

Debt Coverage: A099430's debt is well covered by operating cash flow (31.7%).

Interest Coverage: A099430 earns more interest than it pays, so coverage of interest payments is not a concern.

Balance Sheet

Discover healthy companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/28 14:54
End of Day Share Price 2025/11/28 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Bio Plus Co., Ltd is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hyung Soo KimHanwha Investment & Securities Co., Ltd.
Junghyun KimKyobo Securities Co., Ltd
Jaehee WonShinhan Investment Corp.